[go: up one dir, main page]

PL2474543T3 - Therapeutic agent for mood disorders - Google Patents

Therapeutic agent for mood disorders

Info

Publication number
PL2474543T3
PL2474543T3 PL10813753T PL10813753T PL2474543T3 PL 2474543 T3 PL2474543 T3 PL 2474543T3 PL 10813753 T PL10813753 T PL 10813753T PL 10813753 T PL10813753 T PL 10813753T PL 2474543 T3 PL2474543 T3 PL 2474543T3
Authority
PL
Poland
Prior art keywords
therapeutic agent
mood disorders
mood
disorders
therapeutic
Prior art date
Application number
PL10813753T
Other languages
Polish (pl)
Inventor
Koji Yamada
Tomoyuki Kanda
Original Assignee
Kyowa Hakko Kirin Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649339&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2474543(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co., Ltd. filed Critical Kyowa Hakko Kirin Co., Ltd.
Publication of PL2474543T3 publication Critical patent/PL2474543T3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • C07D491/044Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10813753T 2009-09-02 2010-09-02 Therapeutic agent for mood disorders PL2474543T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2009202893 2009-09-02

Publications (1)

Publication Number Publication Date
PL2474543T3 true PL2474543T3 (en) 2017-09-29

Family

ID=43649339

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10813753T PL2474543T3 (en) 2009-09-02 2010-09-02 Therapeutic agent for mood disorders

Country Status (32)

Country Link
US (1) US9249135B2 (en)
EP (1) EP2474543B1 (en)
JP (1) JP5663484B2 (en)
KR (1) KR101762981B1 (en)
CN (1) CN102482272A (en)
AU (1) AU2010290423B2 (en)
BR (1) BR112012004851B8 (en)
CA (1) CA2772920C (en)
CL (1) CL2012000534A1 (en)
CY (1) CY1119118T1 (en)
DK (1) DK2474543T3 (en)
DO (1) DOP2012000058A (en)
EA (1) EA030333B1 (en)
ES (1) ES2633538T3 (en)
GE (1) GEP20156224B (en)
HR (1) HRP20171137T1 (en)
HU (1) HUE033690T2 (en)
IL (1) IL218321A (en)
LT (1) LT2474543T (en)
MA (1) MA33618B1 (en)
ME (1) ME02804B (en)
MX (1) MX2012002528A (en)
NZ (1) NZ598750A (en)
PL (1) PL2474543T3 (en)
PT (1) PT2474543T (en)
RS (1) RS56345B1 (en)
SI (1) SI2474543T1 (en)
SM (1) SMT201700359T1 (en)
TN (1) TN2012000092A1 (en)
UA (1) UA110097C2 (en)
WO (1) WO2011027805A1 (en)
ZA (1) ZA201202346B (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1700856T3 (en) * 2003-12-26 2016-05-31 Kyowa Hakko Kirin Co Ltd Thiazole derivative
UA113383C2 (en) * 2009-09-02 2017-01-25 THERAPEUTIC AGENT FOR TREATMENT OF ANXIETY DISORDERS
MA41090A (en) * 2014-12-03 2017-10-10 H Lundbeck As LOW-DOSE A2A ANTAGONIST FOR THE TREATMENT OF ADHD AND PARKINSON'S DISEASE
JOP20200093A1 (en) * 2015-01-09 2017-06-16 Kyowa Kirin Co Ltd A method for producing a thiazole derivative
JO3544B1 (en) * 2015-03-19 2020-07-05 Kyowa Kirin Co Ltd A therapeutic agent for frontal lobe dysfunction
TW201803869A (en) 2016-04-27 2018-02-01 健生藥品公司 6-aminopyridin-3-yl thiazoles as modulators of ROR[gamma]t
ES2925473T3 (en) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pyridinyl pyrazoles as modulators of RORyt
JP2021527660A (en) 2018-06-18 2021-10-14 ヤンセン ファーマシューティカ エヌ.ベー. Phenyl and pyridinyl substituted imidazoles as modulators of RORγt
EP3790865A1 (en) 2018-06-18 2021-03-17 Janssen Pharmaceutica NV Phenyl substituted pyrazoles as modulators of roryt
ES2928246T3 (en) 2018-06-18 2022-11-16 Janssen Pharmaceutica Nv 6-aminopyridin-3-yl pyrazoles as RORyt modulators
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331843T2 (en) 1992-07-08 2002-09-26 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives as antidepressants
ATE325610T1 (en) 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk XANTHINE DERIVATIVES FOR THE TREATMENT OF BRAIN SCHEMIA
EP1425017A1 (en) * 2001-09-13 2004-06-09 Schering Corporation Combination of an adenosine a2a receptor antagonist and an antidepressant or anxiolytic
US6620811B2 (en) 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
KR20060037252A (en) 2003-06-10 2006-05-03 교와 핫꼬 고교 가부시끼가이샤 How to treat anxiety disorder
PL1700856T3 (en) 2003-12-26 2016-05-31 Kyowa Hakko Kirin Co Ltd Thiazole derivative
AU2005227997A1 (en) 2004-03-30 2005-10-13 Arena Pharmaceuticals, Inc. Pyrimidine derivatives and methods of treatment related to the use thereof
JPWO2006137527A1 (en) 2005-06-23 2009-01-22 協和発酵キリン株式会社 Thiazole derivative
SI1921077T1 (en) 2005-08-02 2017-11-30 Kyowa Hakko Kirin Co., Ltd. Agent for treating and/or preventing sleep disorder

Also Published As

Publication number Publication date
DOP2012000058A (en) 2012-06-30
SMT201700359T1 (en) 2017-09-07
WO2011027805A1 (en) 2011-03-10
LT2474543T (en) 2017-08-25
AU2010290423B2 (en) 2015-10-29
ES2633538T3 (en) 2017-09-21
CN102482272A (en) 2012-05-30
EP2474543B1 (en) 2017-05-03
MA33618B1 (en) 2012-09-01
BR112012004851B1 (en) 2021-03-02
AU2010290423A1 (en) 2012-04-19
CL2012000534A1 (en) 2012-09-14
EA201270359A1 (en) 2012-09-28
BR112012004851A2 (en) 2016-04-05
EP2474543A4 (en) 2013-05-29
JPWO2011027805A1 (en) 2013-02-04
JP5663484B2 (en) 2015-02-04
CA2772920C (en) 2018-07-31
IL218321A0 (en) 2012-04-30
EP2474543A1 (en) 2012-07-11
NZ598750A (en) 2014-08-29
US9249135B2 (en) 2016-02-02
MX2012002528A (en) 2012-04-11
KR101762981B1 (en) 2017-07-28
BR112012004851B8 (en) 2021-05-25
GEP20156224B (en) 2015-01-26
HUE033690T2 (en) 2017-12-28
CY1119118T1 (en) 2018-02-14
RS56345B1 (en) 2017-12-29
HRP20171137T1 (en) 2017-10-06
IL218321A (en) 2016-10-31
EA030333B1 (en) 2018-07-31
UA110097C2 (en) 2015-11-25
PT2474543T (en) 2017-08-03
CA2772920A1 (en) 2011-10-03
TN2012000092A1 (en) 2013-09-19
US20120184554A1 (en) 2012-07-19
SI2474543T1 (en) 2017-08-31
ZA201202346B (en) 2015-11-25
KR20120047310A (en) 2012-05-11
DK2474543T3 (en) 2017-08-14
ME02804B (en) 2018-01-20

Similar Documents

Publication Publication Date Title
ZA201202346B (en) Therapeutic agent for mood disorders
GB0908957D0 (en) Therapeutic agents
IL214919A0 (en) Method for therapeutic use
IL253293B (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
ZA201108665B (en) Therapeutic agent for motor disorders
EP2510949A4 (en) Therapeutic agent for fibromyalgia
GB0900484D0 (en) Therapeutic agent
ZA201202347B (en) Therapeutic agent for anxiety disorders
IL207906A0 (en) Treatment for ocular-related disorders
GB0910493D0 (en) Therapeutic agents
IL218160A0 (en) Desferrioxamine-metal complexes for the treatment of immune-related disorders
GB0914533D0 (en) Therapeutic agents
GB0919824D0 (en) Therapeutic agents
GB0919829D0 (en) Therapeutic agents
GB0919820D0 (en) Therapeutic agents
GB0919819D0 (en) Therapeutic agents
GB0915586D0 (en) Therapeutic agents
GB0902450D0 (en) Therapeutic agents
GB0919825D0 (en) Therapeutic agents
GB0907971D0 (en) Therapeutic agents
GB0919821D0 (en) Therapeutic agents
GB0911965D0 (en) Therapeutic agents
GB0903949D0 (en) Therapeutic agents